Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Decidual stromal cells (DSCs) are a unique population of mesenchymal-like cells isolated from the maternal decidua of the term placenta. They possess potent immunomodulatory and anti-inflammatory properties, including the inhibition of T-cell proliferation and the secretion of various cytokines and growth factors. In clinical applications, DSCs are typically formulated in a solution containing human albumin to ensure cell stability and viability during infusion. This cell therapy is primarily investigated for the treatment of severe inflammatory conditions such as acute graft-versus-host disease (aGvHD) and acute respiratory distress syndrome (ARDS), where they aim to dampen the cytokine storm and promote tissue repair. The development of this therapy has been led by researchers at the Karolinska Institutet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on decidual stromal cells + human albumin.